Cyprotex: US Business Development Executive Appointment

MACCLESFIELD, UK--(Marketwire - April 15, 2010) -

Thursday 15 April 2010

                              Cyprotex PLC
              ("Cyprotex" or the "Company" or the "Group")

Appointment of Executive Director, Business Development - North America

Cyprotex PLC (AIM: CRX), the drug discovery technology and information
company, announces the appointment of Ben Butterfield as Executive
Director for Business Development in North America. Cyprotex enables
its customers to access secure, high quality Absorption, Distribution,
Metabolism, Excretion / Toxicity (ADMET) data without incurring
significant overheads. Its highly automated platform guarantees high
throughput, reproducibility and rapid turnaround of ADMET data, setting
new industry standards for this sector of the market.

As previously stated, Cyprotex has been restructuring its USA and Rest
of World sales activities as the Company believes that further
investment in the right personnel will allow the Company to establish
its position in these markets and capitalise on the opportunity they
present. Specifically, Ben's appointment will be a key development in
exploiting the opportunity that exists in North America.

Ben was previously Business Development Manager for Toxikon
Corporation, which provides preclinical safety research to medical
device and pharmaceutical companies. He was responsible for the North
East of the US. Ben has a decade's experience of selling products and
services to the healthcare / pharmaceutical industry including two
years at Chantest Inc. where he promoted ADME studies to the
preclinical sector. He has a psychology / premed degree from Loyola
University in New Orleans and is trained in FDA preclinical compliance
regulations.

Ben's appointment is part of an ongoing process to strengthen
Cyprotex's commercial team. Last year, Simon Bury was recruited as
Chief Commercial Officer. Simon has restructured the sales team to
achieve greater effectiveness and has hired a mainland Europe based
Business Development Manager to support European sales. Cyprotex has
also further increased the role of its scientific Study Managers to
strengthen the relationships with current key customers and this has
been and will be central to its success in developing more 'strategic'
customers.

Tony Baxter, Chief Executive of Cyprotex, said:"I am delighted that Ben has
joined Cyprotex. His experience should
transform our efforts in North America where Cyprotex has historically
been underrepresented. As the world's largest pharmaceutical market we
believe that North America represents a significant opportunity and I
am confident that we will make considerable inroads into the market."

For further information:

Cyprotex PLC                               Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
ir@cyprotex.com                            www.cyprotex.com

Execution Noble & Company                  Tel: +44 (0) 20 7456 9191
John Llewellyn-Lloyd
john.llewellyn-lloyd@execution-noble.com
Sam Reynolds
sam.reynolds@execution-noble.com           www.execution-noble.com

Financial Dynamics                         Tel: +44 (0) 20 7831 3113
Ben Brewerton / Ben Atwell / Mo Noonan
cyprotex@fd.com                            www.fd.com




                    This information is provided by RNS
          The company news service from the London Stock Exchange

END